Department of Radiotherapy and Medical Oncology, University Hospital for Tumors, University Hospital Centre "Sisters of Mercy", Ilica 197, 10000, Zagreb, Croatia.
Department of Oncology and Nuclear Medicine, University Hospital Centre "Sisters of Mercy", Vinogradska Cesta 29, 10000, Zagreb, Croatia.
J Craniomaxillofac Surg. 2019 Jan;47(1):80-86. doi: 10.1016/j.jcms.2018.10.003. Epub 2018 Nov 10.
Bone morphogenetic protein 6 (BMP6) has unique properties regarding structure and function in supporting bone formation during development and adult life. Despite its known role in various malignant tumors, the prognostic significance of BMP6 expression in oral squamous cell carcinoma (OSCC) remains unknown. The aim of the study was to investigate immunohistochemical expression of BMP6 in OSCC in correlation with clinical and pathological parameters, disease recurrence and survival. In addition, we investigated other parameters in order to identify prognosticators of neck metastases and final outcome. The study included 120 patients with clinically T1-3N0 OSCC who were primarily surgically treated between 2003 and 2008. There were 99 (82.5%) male and 21 (17.5%) female patients. The five-year disease-specific survival for the whole cohort was 79.7%. Tumors smaller than 2 cm in diameter showed higher incidence of strong BMP6 expression. No statistical correlation was observed between other clinico-pathological factors and BMP6 expression. Expression of BMP6 was not associated with disease recurrence and survival. BMP6 may not serve as prognosticator of final outcome or recurrence in clinically node-negative OSCC subjects. In multivariate analysis predictors of poorer survival were positive surgical margin, moderate tumor cell differentiation and pathological involvement of levels IV and/or V.
骨形态发生蛋白 6(BMP6)在支持发育和成年期骨骼形成方面具有独特的结构和功能特性。尽管其在各种恶性肿瘤中具有已知的作用,但 BMP6 表达在口腔鳞状细胞癌(OSCC)中的预后意义尚不清楚。本研究旨在探讨 BMP6 在 OSCC 中的免疫组织化学表达与临床和病理参数、疾病复发和生存的关系。此外,我们还研究了其他参数,以确定颈部转移和最终结果的预后因素。该研究纳入了 2003 年至 2008 年间经手术治疗的 120 例临床 T1-3N0 OSCC 患者。其中男性 99 例(82.5%),女性 21 例(17.5%)。全队列的 5 年疾病特异性生存率为 79.7%。直径小于 2cm 的肿瘤显示出更高的 BMP6 强表达发生率。其他临床病理因素与 BMP6 表达之间无统计学相关性。BMP6 表达与疾病复发和生存无关。BMP6 可能不能作为临床无淋巴结转移 OSCC 患者的最终结果或复发的预后因素。多因素分析显示,阳性切缘、中度肿瘤细胞分化以及 IV 级和/或 V 级的病理累及是生存率较差的预测因素。